Zurich, Switzerland – In a significant milestone that marks a new chapter in our journey, IMAI MedTech is thrilled to announce that we have been named among the latest winners of the InnoBooster Grant by the esteemed Gebert Rüf Stiftung. Alongside other innovative startups such as Aerospec, NovoViz, and OBaris, IMAI MedTech has been awarded a grant of CHF 150,000 to propel our market entry and further our mission to revolutionize cancer diagnostics through our pioneering 3D histology technology.
The InnoBooster Grant, a highly competitive and prestigious funding program, is designed to support startups that demonstrate groundbreaking innovations with the potential to significantly impact their respective industries. Being recognized by Gebert Rüf Stiftung is not only an honor but also a testament to the hard work, dedication, and innovative spirit of the IMAI MedTech team.
A Leap Forward in Cancer Diagnostics
At IMAI MedTech, our mission is to redefine the landscape of oncology diagnostics. Our cutting-edge 3D histology technology aims to enhance therapeutic outcomes and improve patient care by enabling early and accurate cancer diagnosis. This grant from Gebert Rüf Stiftung will play a crucial role in accelerating our efforts to bring our technology to market, ensuring that healthcare professionals and patients benefit from our innovations sooner.
Empowering Our Vision
The CHF 150,000 InnoBooster Grant will be instrumental in supporting our next phase of growth. These funds will be allocated towards refining our technology, expanding our team, and initiating pilot projects with key healthcare partners. Our goal is to validate the efficacy and benefits of our 3D histology platform in real-world clinical settings, bringing us one step closer to transforming cancer diagnostics globally.
Gratitude and Looking Ahead
We extend our deepest gratitude to Gebert Rüf Stiftung for their support and confidence in IMAI MedTech. This grant is not only a financial boost but also a source of motivation for our team to continue pushing the boundaries of what is possible in medical technology.
As we embark on this exciting phase of development, we remain committed to our vision of making a meaningful impact on the field of cancer diagnosis and treatment. We are eager to leverage this opportunity to accelerate our market entry and look forward to sharing our progress and achievements with our community.
Stay tuned for updates on our journey and the impact of the InnoBooster Grant on our initiatives. Together, we are paving the way for a future where cancer diagnosis is more accurate, efficient, and accessible.
For more information about IMAI MedTech and our innovative solutions, visit our website.
About Gebert Rüf Stiftung
Gebert Rüf Stiftung aims to promote Switzerland as a top location for business and as a place to live. Through its "InnoBooster" program, the foundation supports high-potential startups that contribute to scientific innovation, economic growth, and societal progress.
Contact: For media inquiries and more information about IMAI MedTech, please contact
Comments